RT Journal Article
SR Electronic
T1 Real-world Outcomes in Recurrent/Metastatic Squamous Cell Carcinoma of Head and Neck With Nivolumab: Galician Study
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 1181
OP 1191
DO 10.21873/anticanres.17505
VO 45
IS 3
A1 IGLESIAS, LETICIA
A1 VÍLCHEZ, ROCÍO
A1 AGUÍN, SANTIAGO
A1 GARCÍA, RAMÓN
A1 PENA, CAROLINA
A1 CARRAL, ALBERTO
A1 HUIDOBRO, GERARDO
A1 MOLINA, AUREA
A1 GÓMEZ, JESÚS GARCÍA
A1 COVELA, MARTA
A1 COSTA, MARINHA
A1 MEDINA, ANA
YR 2025
UL http://ar.iiarjournals.org/content/45/3/1181.abstract
AB Background/Aim: Real-world evidence regarding the use of nivolumab in metastatic squamous cell carcinoma of head and neck (R/M SCCHN) is limited. This study aimed to describe the clinical characteristics, outcomes, and safety of nivolumab in R/M SCCHN patients treated in routine clinical practice.Patients and Methods: This retrospective, observational study evaluated the efficacy/safety of nivolumab in 116 patients with R/M SCCHN treated at nine centers within the Galician Group of Head and Neck Cancer health network between 2017 and 2019.Results: Basal characteristics of patients included a median age of 60 years, ECOG performance status −2 (14%) and −3 (1%) and a first diagnosis of stage IV a/b/c (74%). Nivolumab was used as first line, second line, and third line therapy in 17%, 66%, and 17% of patients, respectively. After a median follow-up of 14 months (range=1-69 months), the median progression-free survival was 2.30 months (95%CI=1.45-3.14) and the median overall survival was 8.1 months (95%CI=5.93-10.23). Outcomes were better when nivolumab was administered earlier in treatment course. Grade 3/4 adverse events were observed in 21.27% of patients.Conclusion: These findings support the efficacy and safety of nivolumab in the real-world treatment of R/M SCCHN.